A biotech startup operating out of New York City is openly challenging one of the most firmly established ethical and legal boundaries in modern science: the prohibition on creating genetically modified human babies. The company, Origin Genomics, is making the case that editing disease-causing genes in human embryos may be a risk worth taking, even though such work is currently illegal in most of the world, including the United States.
The firm's founder and chief executive, Cathy Tie, recently gave NPR an exclusive tour of the company's laboratory facilities, asking that the precise location be withheld for security reasons. The visit offered a rare look inside an operation that sits at the center of a long-running international controversy over how far science should go in altering the human genetic code.
During the tour, Tie, dressed in a white lab coat bearing her name and the company's logo, walked reporters through the workspace where the startup is testing its technology for repairing defective genes. The lab is outfitted with the kind of specialized equipment one would expect from a company pushing at the frontiers of genetic medicine.
Among the most striking features is a gray metal tank sitting on the floor that resembles an oversized thermos. Tie explained that it is a cryogenic storage unit filled with liquid nitrogen, the ultra-cold substance used to preserve biological material at extremely low temperatures over long periods. The tank serves as the repository for the embryos central to Origin Genomics' research.
According to Tie, the container holds human embryos that carry mutations responsible for serious genetic diseases. When she opened the vessel's black lid, white vapor from the liquid nitrogen drifted into the air. She then carefully removed a long metal rod holding several frosted glass tubes at its tip, each one designed to hold a small number of embryos.
The embryos were donated by married couples whose families have suffered for generations from life-threatening inherited disorders, according to the source material. For these families, the possibility of gene editing represents something deeply personal rather than abstract: the hope of having children who are free of the conditions that have afflicted their relatives.
Origin Genomics' approach involves extracting stem cells from the donated embryos so its scientists can test the technology's ability to correct the faulty genes. The company frames its central mission as demonstrating that the potential benefits of editing disease-causing genes in human embryos can outweigh the risks associated with the procedure.
That position places the startup in direct tension with existing laws. Creating gene-edited babies is illegal in numerous countries, a prohibition rooted in both safety concerns and ethical objections. The widespread ban followed a major international controversy years ago, when a Chinese scientist stunned the world by announcing the birth of twin girls whose genes he had altered, an act that drew near-universal condemnation from the scientific community.
Despite that history, Origin Genomics argues that it may be time to reconsider the blanket prohibition. The company's reasoning rests on the idea that not all gene editing is the same. Editing genes to prevent devastating inherited diseases, its leaders suggest, is a fundamentally different proposition from altering traits for enhancement purposes, such as selecting for height, intelligence, or appearance.
Critics of heritable gene editing typically raise several concerns. One is that changes made to embryos would be passed down to future generations, meaning any unintended consequences could ripple through a family line indefinitely. Another is the risk of off-target edits, in which the editing tools alter DNA in places other than the intended site, potentially causing harm that may not become apparent for years.
Supporters of the research counter that the technology has advanced considerably and could offer a path to eliminating certain genetic disorders entirely. For families carrying mutations for conditions that cause severe illness or early death, they argue, the alternative options are limited and often unsatisfactory. Some couples facing these circumstances currently rely on screening procedures that select healthy embryos or use donated genetic material, but these approaches do not work in every case.
Tie and her team appear to be betting that a careful, research-driven approach can convince regulators and the public that the benefits justify revisiting the current legal framework. The company's lab work is focused on demonstrating the precision and reliability of its methods before any broader conversation about clinical use can credibly advance.
Yet the ethical questions remain formidable. Even if the science proves sound, questions about consent, equity, and the long-term societal implications of modifying the human germline would persist. Who would have access to such treatments? Would they deepen existing inequalities? How would oversight be structured across borders when some nations might permit what others forbid?
For now, Origin Genomics occupies an unusual position: a company whose core ambition is currently against the law, working to build the scientific foundation that might, in its view, one day justify changing that law. Whether its research persuades policymakers and the public, or simply reignites a debate many would prefer to leave settled, remains to be seen. What is clear is that the frozen embryos stored in that New York lab represent a question the world has not yet finished answering.
(0)